Benzinga | Jun 8, 2021 08:14AM EDT

Twist Bioscience Begins Shipping Of Synthetic RNA Controls For Kappa SARS-CoV-2 Variants

Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 Kappa (B.1.617.1) variant strain. The company is also working on controls for the SARS-CoV-2 Delta (B.1.617.2) and B.1.617.3 variants. All three variants were first identified in India.